| Autor: |
Michael V. D’Ambrosio, Jennifer A. Doudna, Amy Kistler, Katherine S. Pollard, G. Renuka Kumar, Daniela Boehm, Gavin J. Knott, Chunyu Zhao, Abdul Bhuiya, Carley N. Gray, Max Armstrong, Melanie Ott, Jeannette M. Osterloh, María Díaz de León Derby, Emily D. Crawford, Jeffrey H Shu, Sungmin Son, Joseph L. DeRisi, Chia-Lin Tsou, Parinaz Fozouni, Stephanie I Stephens, Andrew R. Harris, Anke Meyer-Franke, Neil A. Switz, Andreas S. Puschnik, Maira Phelps, Daniel A. Fletcher, Charles Langelier |
| Rok vydání: |
2020 |
| Předmět: |
|
| DOI: |
10.1101/2020.09.28.20201947 |
| Popis: |
SUMMARYThe December 2019 outbreak of a novel respiratory virus, SARS-CoV-2, has become an ongoing global pandemic due in part to the challenge of identifying symptomatic, asymptomatic and pre-symptomatic carriers of the virus. CRISPR-based diagnostics that utilize RNA and DNA-targeting enzymes can augment gold-standard PCR-based testing if they can be made rapid, portable and accurate. Here we report the development of an amplification-free CRISPR-Cas13a-based mobile phone assay for direct detection of SARS-CoV-2 from nasal swab RNA extracts. The assay achieved ∼100 copies/μL sensitivity in under 30 minutes and accurately detected a set of positive clinical samples in under 5 minutes. We combined crRNAs targeting SARS-CoV-2 RNA to improve sensitivity and specificity, and we directly quantified viral load using enzyme kinetics. Combined with mobile phone-based quantification, this assay can provide rapid, low-cost, point-of-care screening to aid in the control of SARS-CoV-2. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
